Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / GC Biopharma Corp

Clinicaltrial registered20 Oct 2026

GC Biopharma Corp

20 Oct 2026: Trial registered · Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
20 Oct 2026
Title
Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
Conditions
Influenza A, Influenza B, Influenza Vaccination
Phase
Phase 2, Phase 3
Study Type
Interventional
Status
Recruiting
Countries
South Korea
Country
South Korea
Reference
NCT07883928
Location
South Korea
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at GC Biopharma Corp

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for GC Biopharma Corp in our registers.

More from South Korea

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.